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The microenvironment at the site of tumor metastasis plays a key role in determining the fate of the metastasizing tumor cells.
This ultimately has a direct impact on the progression of cancer. Bone is the preferred site of metastasis of breast cancer. Painful,
debilitatingosteolyticlesionsareformedasaresultofcrosstalkbetweenbreastcancercellsandcellsinthebone,predominantlythe
osteoblastsandosteoclasts.Inthispaper,wehavediscussedthetemporalandspatialroleofhedgehog(Hh)signalingininﬂuencing
the fate of metastatic breast cancer cells in bone. By virtue of its secreted ligands, the Hh pathway is capable of homotypic
and heterotypic signaling and consequently altering the microenvironment in the bone. We also have put into perspective the
therapeutic implications of using Hh inhibitors to prevent and/or treat bone metastases of breast cancer.
1.Introduction
The overwhelming numbers of cancer patients (≥90%) that
die due to the dissemination of cancer cells rather than the
primary tumor throw the process of metastasis to the centre
stage of clinical management of cancer [1]. However, even as
weembarkonthisreview,themostpoorlyunderstoodaspect
of the pathogenesis and progression of cancer is the process
of metastasis of the tumor.
Evolving literature supports that metastasis is a second
disease imposed on the primary tumor. The outcome of
metastasis is determined by the interplay between the sub-
population of metastatic cells and host homeostatic factors
in the speciﬁc organ microenvironment [2]. The metastatic
cascade can be conceptually organized and simpliﬁed into
two major phases: (i) physical translocation of a cancer
cell from the primary tumor to the microenvironment of a
distant tissue (Figure 1) and (ii) colonization of secondary
site (Figure 2)[ 3].
The metastasizing tumor cells hijack many of the path-
ways that play major roles during normal development.
Many of the embryonic developmental signaling pathways,
such as the Wnt, Hedgehog (Hh), and Notch pathways,
aﬀect the survival of tumor stem cells and orchestrate a
complex microenvironment that promotes tumor survival
and progression. In this review, we will highlight the sig-
nificance of the Hh pathway in developmental biology and
our present understanding of its role in regulating breast
cancer metastasis to bone. We will elaborate how a pathway
t h a ti ss oc r i t i c a li nn o r m a ld e v e l o p m e n to ft h ee m b r y oi s
usurped by the breast cancer cells to serve their own purpose
of invading the tissue of its origin, extravasation, survival
during translocation, and adaptation at the distant site to
bring about proliferation and colonization.
2.The HhPathway inNormalDevelopment
The Hh pathway plays a central role in embryonic devel-
opment and maintenance of stem or progenitor cells in
many adult tissues [4]. The Hh family of secreted proteins
signal through both autocrine and paracrine mechanisms to
c o n t r o lc e l lp r o l i f e r a t i o n ,d i ﬀerentiation, and morphology
[5]. The ligands comprise desert hedgehog (DHH), Indian
hedgehog (IHH), and Sonic hedgehog (SHH). Hh signaling
in mammalian cells is mediated by the GLI family of zinc
ﬁnger transcription factors comprising GLI1, GLI2, and
GLI3. GLI1 is a strong transcriptional activator; GLI2 can
functionasanactivatororarepressorinacontext-dependent
manner; GLI3 is mostly a repressor [6]. In its classical form,2 International Journal of Breast Cancer
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Figure 1: Hh signaling conditions the milieu to support metastasis of breast cancer cells to the bone. Depicted here is the ﬁrst of the two
microenvironments, the milieu of the primary tumor. Hh signaling in the tumor cells impacts the stromal cells in the environment, which in
turn amplify paracrine Hh signaling by producing growth factors that propel epithelial-mesenchymal transition. Concomitantly, secreted,
soluble proteins produced by the primary tumor contribute towards conditioning the secondary site for the arrival of the tumor cells.
in the absence of the ligand, the Hh-signaling pathway is
inactive, GLI1 is sequestered in the cytoplasm and repressed
for its transcription activity. Binding of the Hh ligands to the
receptor, a 12-pass transmembrane protein called patched-
1 or patched-2 (PTCH1 or -2), releases the inhibitory aﬀect
of PTCH on a serpentine protein called Smoothened (SMO)
[7]. SMO gets hyperphosphorylated and localizes to primary
cilia where [8] GLI1 is activated by release from a large
protein complex and translocates to the nucleus to function
as a transcriptional activator [9] of several target genes,
including PTCH, insulin-like growth factor-binding protein
and cyclin D2 [10].
The involvement of the Hh pathway, in particular the
ligand SHH, with the skeletal system begins with embryonic
development, where SHH is expressed in the notochord, the
ﬂoorplateoftheneuraltube,thebrain,thezoneofpolarizing
activity in the developing limbs, and the gut [11, 12]. SHH
speciﬁcally functions in many diﬀerent ways to contribute to
the patterning of a developing embryo in a concentration-
dependent manner along a target range [13]. A variety of
embryonic defects and diseases result from mutations in the
Hh pathway [14]. The long-range morphogenic properties
of SHH signaling are also evident in the development of the
CNS [15]. Thus, temporal and spatial regulation of SHH
signaling is key to proper organogenesis. However, in the
adults, this pathway is mainly inactive [16] and may play
a role in the maintenance and renewal of normal stem cell
population in the nervous system [17]. Moreover, Lavine
et al. reported that the Hh signaling is essential for cardiac
function at the level of the coronary vasculature [18].
3. The Hedgehog PathwayinCancer
The Hh pathway is required for normal proliferation of hu-
man melanocytes in vitro and for proliferation and survivalInternational Journal of Breast Cancer 3
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Figure 2: Breast cancer cells armed with Hh signaling disrupt the dynamic equilibrium in the bone to serve its purpose of self propagation
and subsequent osteolysis. Breast cancer cells engane in a crosstalk with osteoblasts and osteoclasts. This cumulatively results in the
diﬀerentiation and activation of osteoclasts and eventually leads to enhancing osteolysis and growth of breast tumor cells in the bone.
Overall, this ﬁgure addresses the role of Hh signaling in the vicious cycle of osteolytic metastasis of breast cancer.
of human melanoma in vivo [19, 20]. In esophageal squa-
mous cell carcinoma, GLI1 expression has been associated
with lymphatic metastasis [21], while in breast cancer, strong
nuclearGLIstainingwasobserved[22].Lietal.haverecently
reported that pancreatic cancer stem cells express high levels
of SHH [23]. This is interesting given the implications
for SHH in adult stem cell renewal, in pancreatic ductal
progenitor cells, and also in adult hair follicle stem cells
[24]. SHH is misregulated in pancreatic adenocarcinoma,
prostate adenocarcinoma, esophageal and stomach cancer,
and nonsmall cell carcinoma [14]. As such, Hh signaling has
been shown to be active in multiple cancer types [22, 25–48]
(Table 1).
Active Hh signaling is also found to inﬂuence the tumor
stromal microenvironment [27] and supports stem cells in
the tumor in an undiﬀerentiated, proliferative state [26,
50]. SHH is not only a mediator of angiogenesis but has
also been shown to induce vessel formation in endothelial
cells [51] and activate expression of angiopoietins I and
II, and VEGF-signaling proteins from mesenchymal cells,
highlighting the signiﬁcance of tumor-associated ﬁbroblasts
in combination with canonical Hh signaling to mediate4 International Journal of Breast Cancer
Table 1: Cancers with aberrant activation of Hh signaling.
Milieu Hh Signaling
caused by
Molecule(s)
involved Type of cancer Reference
I Overexpression GLI1 Glioblastoma [30]
Mutations PTCH Basal cell carcinoma (BCC) [31, 32]
SMO Basal cell carcinoma [31, 32]
PTCH Medulloblastoma [33]
PTCH Rhabdomyosarcoma [34]
PTCH1 Gorlin syndrome BCC [35, 36]
SMO & PTCH1 Nonfamilial BCC [37]
II Ligand-dependent
autocrine Breast [22]
Pancreatic [38]
Lung cancer [39]
Oesophagal [40]
Prostate [41]
Gastric adenocarcinoma [42]
Colorectal [43]
Hepatocellular
adenocarcinoma [44]
Ovarian carcinoma [45, 49]
Ligand-dependent
paracrine Pancreatic [46–48]
Milieu I represents the microenvironment of the primary tumor; Milieu II represents the microenvironment at the metastatic site.
blood vessel formation [52]. Cancer cells utilize abnormal
Hh signaling (both autocrine and paracrine) to inﬂuence
proliferation and diﬀerentiation of their surrounding envi-
ronment.
The role of Hh signaling in cancer has been revealed
by studies that have manipulated the expression of the GLI
transcription factors or the ligands or upon treatment with
pharmacologic inhibitors that restrict Hh signaling. In pan-
creatic cancer cell lines, disruption of Hh signaling by the
inhibitor cyclopamine, inhibited epithelial-mesenchymal-
transition (EMT) [53, 54]. Tumor burden and metastasis
in both prostate and pancreatic adenocarinomas were also
reduced as a result of Hh signaling inhibition [53, 55].
In contrast, enforced expression of GLI1 induced the
expression of Snail [56], an EMT marker. Conversely, we
observed loss of mesenchymal markers upon abrogation
of GLI1 expression [19]. Overall, GLI1 silencing had a
pronounced eﬀect on tumor malignancy in vivo by reducing
metastasis. We also reported that signaling via the Hh
pathway transcriptionally upregulates OPN [19]. OPN is
a secreted protein that inﬂuences multiple downstream
signaling events that allow cancer cells to resist apoptosis,
invade through extracellular matrix, evade host immunity
[57], and inﬂuence growth of indolent tumors [58, 59].
OPN constitutes a component of the secretome of several
melanoma-derived cell lines [60, 61] and is also expressed in
metastatic breast cancer cell lines [62]. It is highly probable
that active Hh signaling in a subset of cancer cells can
be propagated in a paracrine manner by OPN secreted
into the tumor microenvironment. OPN, by virtue of its
ability to signal through multiple receptors, can promote
malignant behavior in neighboring cancer cells, regardless
of the status of the Hh pathway, thereby propagating
paracrine Hh signaling. Thus, at the site of origin, the breast
tumor cells not only potentiate their own aggressiveness by
inﬂuencing the neighboring cells, but also send signals to
the secondary target organ to condition for relocalization
[58, 63, 64].
For the purpose of this review, we have focused the
remainder of the article on discussing the role of Hh sig-
naling in impacting breast cancer metastasis to the bone.
This complication of breast cancer continues to present a
challenge to oncologists and reduces the chances of survival
forbreastcancerpatients.Amongbreastcancersthatbecome
aggressive, metastasis to bone marrow is common. Detection
of bone metastasis often signals the onset of the life-
threatening phase of breast cancer. The 5-year survival rate is
98% for breast cancer when detected early; this precipitously
drops to 83% for patients initially diagnosed with regional
spread and to 26% for those with distant metastases. In the
following sections, we will discuss the role of Hh signaling
in mediating a crosstalk between breast cancer cells and cells
in the bone and the overall impact on the ability of breast
cancer cells to sculpt the bone microenvironment and cause
osteolysis (Figures 1 and 2).
4. The Bone Microenvironment
The bone microenvironment comprises osteoblasts, osteo-
clasts, mineralized bone matrix, and other cell types, suchInternational Journal of Breast Cancer 5
as the osteocytes embedded within bone. Of these, the
most important ones (from the perspective of this arti-
cle) are the bone-resorbing osteoclasts and bone-forming
osteoblasts.
Osteoblasts are derived from mesenchymal stem cells,
which can also give rise to chondrocytes, ﬁbroblasts, my-
ocytes, or adipocytes [65]. Formation of new bone and
the regulation of osteoclastogenesis through expression of
RANKL and OPG are two main functions of the osteoblasts.
V a r i o u sg r o w t hf a c t o r sa n dh o r m o n e sl i k eB M P s ,P T H r P ,
TGFβ, and so forth are known to take part in the diﬀer-
entiation of preosteoblasts into mature osteoblasts. Even-
tually, mature, mineralizing osteoblasts become embedded
in the newly secreted bone matrix and undergo terminal
diﬀerentiation to form osteocytes. Although the osteocytes
have much reduced activity as compared to osteoblasts,
their long processes allow them to connect the entire
matrix via a series of canaliculi. It is understood that the
osteocytes ensure communication between sites deep in the
bone and the extraosseous world; they create an enormous
increase in mineral surface exposed to extracellular ﬂuid
and cellular activity and function as mechanosensory cells of
bone, involved in the transduction of mechanical loads into
biochemical signals [66].
Osteoclasts, on the other hand, are large multinucleated
terminally diﬀerentiated cells with a unique ability for
bone resorption [67]. They are derived from hematopoietic
stem cells. The cells undergo proliferation in response to
M-CSF. The precursor cells ﬂaunt receptor activator of
nuclear factor κB (RANK) on the surface, while the ligand
RANKL is expressed by the bone marrow stromal cells and
osteoblasts. Binding of the ligand to the receptor com-
mits the precursor cells to the osteoclast lineage. The
same interaction is also critical for osteoclast formation
and can also promote osteoclast activity, since RANK
is also present on the surface of terminally diﬀerenti-
ated osteoclasts. The fusion of osteoclast precursor cells
results in the formation of large multinucleated active
osteoclasts.
Osteoprotegerin (OPG) is a soluble decoy receptor and
a competitor of RANKL in its binding with RANK and
thus can inhibit osteoclastogenesis. Therefore, the balance
of RANKL and OPG is critical for osteoclast formation and
activity. Osteoclasts attach to the bone surface via actin-
richpodosomesenablingthemtoformsealedzoneswithruf-
ﬂed borders. Proteolytic enzymes such as CTSK (Cathepsin
K) and MMPs are secreted into this isolated environment,
resulting in degradation of the bone matrix, dissolution
of the bone mineral, and resorption of the bone [68].
Evidently behind its outward rigidity, bone is a highly
dynamic organ where homeostasis is tightly controlled and
largely dependent upon cellular communication between
osteoclasts and osteoblasts. This tight coupling between
bone resorption and bone formation is essential for the
correct function and maintenance of the skeletal system,
repairing microscopic skeletal damage, and replacing aged
bone. Any deviation from this homeostasis results in a range
of pathologic diseases, including osteoporosis and cancer-
induced bone disease.
5.The Metastasisof BreastCancer Cellsto
the Bone
The vertebral venous system is the most common mode
of transport of breast cancer cells from the breast to bone
[69]. This allows breast cancer cells to come into contact
with the axial skeleton, including the ribs, spine, pelvis, and
proximal humerus and femur, which is the main distribution
of bone metastases in breast cancer patients [70]. Tumor
cells,evenattheirsiteoforigin,sendsignalstotheirpreferred
secondary site [64] of metastasis. This modulates the micro-
environment of that region. It is likely that the Hh ligands
and secreted factors such as IGFs and OPN may impact
this “homing” mechanism. It can be speculated that the
factors secreted by breast cancer cells create a “premetastatic
niche” as termed by Lyden and colleagues [64, 71]. The
role of chemokines and cytokines as well as the homing
mechanism has also been elaborately discussed in a review
by Bussard et al. [72]. Our ﬁndings show that expression
and secretion of Hh ligands by the breast cancer cells
augments these processes (Figure 1). Once malignant cells
have migrated to the bone, their ability to colonize is facil-
itated by the bone microenvironment. MMPs, chemokine
receptor 4 (CXCR4), VEGF, and connective tissue growth
factors supposedly target metastatic tumor cells to bone and
facilitate their survival within the bone microenvironment
[73,74].Physicalfactorswithinthebonemicroenvironment,
including hypoxia, acidic pH, and extracellular calcium, and
bone-derived growth factors, such as TGF-β and insulin-like
growth factors activate tumor expression of VEGF, PDGF,
and endothelin (ET-1) [75] .F a c t o r ss u c ha sP T H r P ,T G F -
β, and IL-11 produced by breast cancer cells favor osteoclast
maturation and osteolysis, leading to the release of growth
factors that stimulate malignant tumor growth [76]. In fact,
expression of IL-11 and OPN by breast cancer cells has been
found to be critical for the osteolytic activity of breast cancer
cells [74]. Thus, signals from the breast cancer cells at their
primary site might trigger a cascade of events involving the
osteoblast-mediated initiation of osteoclastogenesis which
releasesaplethoraofgrowthfactorsinthebonemilieuwhich
not may only act as chemoattractants for the “metastasis-
enabled” breast cancer cells but also favor the latter’s estab-
lishment and further proliferation once they have migrated
to the bone. This would in turn tilt the balance in favor of
osteoclastogenesis as more favorable factors are then readily
available to the osteoclasts in the bone milieu itself and
thus would lead to a self-perpetuating vicious cycle of events
(Figure 2).
6. Hh Signalinginthe Bone Microenvironment
Hh-signaling-activated GLI2 transcription mediates osteo-
blast diﬀerentiation [77]. This is likely due to the regu-
lated expression of bone morphogenetic protein-2, BMP-2,
that is involved in osteogenic diﬀerentiation by promoting
commitment of mesenchymal stem cells to the osteoblast
lineage. GLI2 transcriptionally activates BMP-2 expression
and also synergizes with BMP-2 in osteoblasts [78]. These
contentions are contradicted by Plaisant et al. who have6 International Journal of Breast Cancer
reportedthatHhsignalingcausesadecreaseintheexpression
of Runx2, a key transcription factor that regulates osteoblast
diﬀerentiation [79]. It is proposed that Hh signaling may be
regulating different aspects of bone formation in rodent and
human systems.
OPN is one of the abundant noncollagenous proteins
in bone. It promotes osteoclast function and is consistently
overexpressed in highly metastatic cells. OPN accumulates
at cement lines in remodeling bone [80] and is localized
to cell-matrix and matrix-matrix interfaces in mineralized
tissue, where it is deposited by actively resorbing osteoclasts.
OPN positively impacts osteoclast formation, migration,
and resorptive activity [81, 82]. We recently reported that
OPN is regulated, in part, by the Hh pathway [19]. We
have also shown that breast cancer cells express Hh ligands
and engage in a crosstalk with osteoblasts and osteoclasts
[83]. Our recent studies (communicated to Breast Cancer
Research) have shown that the Hh pathway plays a role in
initial osteoblasts maturation, especially in the presence of
breast cancer cells (Figure 2). Following an initial accelerated
diﬀerentiation process, characterized by the expression of
alkaline phosphatase and expression of collagenous and
noncollagenous matrix proteins such as BSP and OPN
and osteoclast-maturation proteins including RANKL and
PTHrP, the osteoblasts appear to undergo apoptosis.
The Hh ligands also mediate a direct dialogue between
breast cancer cells and preosteoclasts and induce changes
in preosteoclasts that inﬂuence the production of OPN and
essential bone-resorbing proteases, CTSK, and MMP9 by
osteoclasts [83]. Thus, Hh ligands produced by the metas-
tasizing breast cancer cells are instrumental in initiating a
crosstalk directly with osteoclasts and promote osteoclast
diﬀerentiation and resorption activity (Figure 2). Breast
cancer cells also express PTHrP as a result of Hh signaling,
further amplify paracrine Hh signaling in the bone microen-
vironment, and add to the overall osteolytic conditions [84].
Thus, the vicious cycle of bone metastasis involves a
complex crosstalk between the metastasizing breast tumor
cells and the bone microenvironment through multiple
extracellular factors and signaling pathways with the Hh
pathway playing an essential role. Based on our ﬁndings, we
would like to propose that the newly arrived breast tumor
cellsinduceinitialosteoblastdiﬀerentiationwhichstimulates
osteoclastdiﬀerentiation.Soon,thesituationisoverwhelmed
byosteoclastdiﬀerentiationfollowedbyintenseboneresorp-
tion leading to the local release of generous amounts of
growth factors that not only encourage their growth but also
alter their phenotype, making them (cancer cells) resistant
to standard cytotoxic antitumor treatments see the appendix
[85, 86].
7. Conclusion
The bone microenvironment with ongoing bone resorp-
tion almost resembles sites of wound healing. The bone
stroma is almost guaranteed to provide hospitable sites
for disseminating colonization-competent breast cancer cells
[61]. This ensures the successful proliferation and ultimate
colonization of the bone by metastasizing breast tumor cells.
The crosstalk between the metastasizing breast cancer cells
andthebonecells,namely,theosteoblastsandtheosteoclasts
occurs in a fashion that not only favors proliferation of
the newly arrived tumor cells in the bone milieu but also
ultimately the complete subjugation of the resident (bone)
pathways to serve the purpose of establishment and well-
being of the tumor cells with concurrent destruction of the
host environment. Therefore, it is essential to understand
the interactions between tumor and bone and identify
microenvironment-selectiveagentstohalttumorgrowthand
bone metastasis thereby reducing the morbidity of skeletal
related events [62]. Thus, given the fact that breast cancer
cells express Hh ligands and that Hh signaling propels
breast cancer progression, it is likely that administration
of pharmacological Hh inhibitors can inhibit Hh signaling
in both breast cancer cells and osteoclasts and may reduce
breast-cancer-mediated bone loss in metastatic disease. This
strategy targets the tumor cells as well as the bone and
its microenvironment and can reduce tumor burden and
tumor-derived bone lesions.
Appendix
Some of the Key Players in Osteolytic Metastasis of Breast
Cancer
BMP: bone morphogenetic protein, a group of cytokines
responsible for the tissue architecture throughout the
body.
IGF: insulin-like growth factors are responsible for cell
proliferation and form the IGF axis.
PDGF: platelet derived growth factor, a secreted molecule
that regulates growth and cell division.
PTHrP: parathyroid hormone-related protein is a hormone
that regulates endochondral bone development and
also regulates epithelial mesenchymal interactions in
mammary gland formation. It is secreted by several
cancer cells.
MMPs: matrix metalloproteases are zinc-dependent en-
dopeptidases, capable of degrading all kinds of extra-
cellular matrix proteins and processing a number
of bioactive molecules. They play a major role on
cell proliferation, migration (adhesion/dispersion),
diﬀerentiation, angiogenesis, apoptosis, and host de-
fense.
OPG: osteoprotegerin (OPG), also known as osteoclastoge-
nesisinhibitoryfactor(OCIF),ortumornecrosisfac-
torreceptorsuperfamilymember11B(TNFRSF11B),
is a basic glycoprotein that is a decoy receptor for the
receptor activator of nuclear factor kappa B ligand
(RANKL) and can inhibit osteoclastogenesis.
RANK: receptor activator of nuclear factor κB (RANK), also
known as TRANCE Receptor, is a type I membrane
protein expressed on the surface of osteoclasts and is
involved in their activation upon ligand binding.International Journal of Breast Cancer 7
RANKL: receptor activator of nuclear factor kappa B ligand,
alsoknownastumornecrosisfactorligandsuperfam-
ily member 11 (TNFSF11), TNF-related activation-
induced cytokine (TRANCE), osteoprotegerin ligand
(OPGL), and osteoclast diﬀerentiation factor (ODF).
I tf u n c t i o n sa sak e yf a c t o rf o ro s t e o c l a s td i ﬀerentia-
tion and activation.
TGF-β: transforming growth factor beta is an antiprolifera-
tive factor protein that controls proliferation, cellular
diﬀerentiation, and other functions in most cells.
VEGF: vascular endothelial growth factor is a signal protein
produced by cells that stimulates vasculogenesis and
angiogenesis.
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